[{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"ARCA Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"ORKA-001","moa":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Oruka Therapeutics \/ Oruka Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Oruka Therapeutics \/ Oruka Therapeutics"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Fairmount","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"ORKA-001","moa":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Oruka Therapeutics","amount2":0.28000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Oruka Therapeutics \/ Fairmount","highestDevelopmentStatusID":"5","companyTruncated":"Oruka Therapeutics \/ Fairmount"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Braidwell LP","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Private Placement","leadProduct":"ORKA-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Oruka Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Oruka Therapeutics \/ Braidwell LP","highestDevelopmentStatusID":"14","companyTruncated":"Oruka Therapeutics \/ Braidwell LP"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"ARCA Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Merger","leadProduct":"ORKA-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Oruka Therapeutics \/ Oruka Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Oruka Therapeutics \/ Oruka Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Oruka Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The net proceeds from the financing will be used to support the clinical development of ORKA-001, currently being evaluated in early-stage clinical trials for the treatment of psoriasis.

                          Brand Name : ORKA-001

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          September 12, 2024

                          Lead Product(s) : ORKA-001

                          Therapeutic Area : Dermatology

                          Highest Development Status : IND Enabling

                          Sponsor : Braidwell LP

                          Deal Size : $200.0 million

                          Deal Type : Private Placement

                          blank

                          02

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Through the merger, the company will focus on advancing Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) for the treatment of plaque psoriasis.

                          Brand Name : ORKA-001

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          August 29, 2024

                          Lead Product(s) : ORKA-001

                          Therapeutic Area : Dermatology

                          Highest Development Status : IND Enabling

                          Recipient : ARCA Biopharma

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          03

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Through the merger, the company will focus on advancing Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) for the treatment of plaque psoriasis.

                          Brand Name : ORKA-001

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 03, 2024

                          Lead Product(s) : ORKA-001

                          Therapeutic Area : Dermatology

                          Highest Development Status : IND Enabling

                          Recipient : ARCA Biopharma

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          04

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The net proceeds will be used to advance Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) for the treatment of plaque psoriasis.

                          Brand Name : ORKA-001

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 03, 2024

                          Lead Product(s) : ORKA-001

                          Therapeutic Area : Dermatology

                          Highest Development Status : IND Enabling

                          Sponsor : Fairmount

                          Deal Size : $275.0 million

                          Deal Type : Private Placement

                          blank